How to evaluate Medicaid buy-in proposals

In the midst of threats to the Affordable Care Act and pushes for more dramatic shifts to single-payer healthcare, some Democrats in Congress and state legislatures have begun proposing a different option: allowing people to buy into Medicaid. But not all those proposals would achieve their goals in the same way, argue Duke University researcher David Anderson, MSPPM, and Harvard University PhD student and former CMS spokesperson Emma Sandoe.

Writing in a blog for Health Affairs, Anderson and Sandoe said Medicaid buy-in proposals can be largely divided into two camps: those which would require a CMS waiver to create a new eligibility category in Medicaid and policies which would use the framework of managed care contracts to offer a “public option” on ACA exchanges.

Both methods share common goals, like offering a lower-cost option than the current plans on the exchanges, where premiums on popular silver-level plans jumped by an average of 34 percent for 2018 coverage. Pricing those plans would be a challenge, Anderson and Sandoe wrote, and create an unintended consequence for other ACA customers.

“The introduction of more low-price plans may reduce the benchmark plan price, which determines the amount of premium subsidies for those who are eligible,” they wrote. “A lower-cost benchmark would raise effective premiums for many subsidized buyers. This problem disappears if Medicaid buy-in is only offered on a nonsubsidized basis.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.